Access Bio, Inc. (KOSDAQ:950130)

Market Cap	185.01B
Revenue (ttm)	74.42B
Net Income (ttm)	-21.64B
Shares Out	35.17M
EPS (ttm)	-634.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100,049
Average Volume	166,306
Open	5,350.00
Previous Close	5,330.00
Day's Range	5,250.00 - 5,355.00
52-Week Range	4,380.00 - 11,100.00
Beta	0.24
RSI	47.28
Earnings Date	Nov 14, 2025

About Access Bio

Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide. The company provides Covid-19 detection kits, which are tests for assessing the current or past presence of SARS-CoV-2.; rapid diagnostic tests, suitable for preliminary diagnosis or emergency medical screening in medical facilities with limited resources; analyzers, designed to measure different chemicals and other characteristics in biological samples; and molecular diagnostic solu...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2002
• Employees: 101
• Stock Exchange: KOSDAQ
• Ticker Symbol: 950130

Financial Performance

In 2024, Access Bio's revenue was 112.46 billion, a decrease of -67.74% compared to the previous year's 348.64 billion. Losses were -347.58 million, -89.05% less than in 2023.